These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11099249)

  • 21. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.
    Hua X; Zhou L; Liu P; He Y; Tan K; Chen Q; Gao Y; Gao Y
    J Thromb Thrombolysis; 2014 Jul; 38(1):57-64. PubMed ID: 24671732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
    Molina CA; Ribo M; Rubiera M; Montaner J; Santamarina E; Delgado-Mederos R; Arenillas JF; Huertas R; Purroy F; Delgado P; Alvarez-Sabín J
    Stroke; 2006 Feb; 37(2):425-9. PubMed ID: 16373632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots.
    Colasuonno M; Palange AL; Aid R; Ferreira M; Mollica H; Palomba R; Emdin M; Del Sette M; Chauvierre C; Letourneur D; Decuzzi P
    ACS Nano; 2018 Dec; 12(12):12224-12237. PubMed ID: 30427660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
    Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
    Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
    Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
    Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes.
    Shaw GJ; Meunier JM; Huang SL; Lindsell CJ; McPherson DD; Holland CK
    Thromb Res; 2009 Jul; 124(3):306-10. PubMed ID: 19217651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
    Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
    J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research.
    Hua X; Liu P; Gao YH; Tan KB; Zhou LN; Liu Z; Li X; Zhou SW; Gao YJ
    J Thromb Thrombolysis; 2010 Jul; 30(1):29-35. PubMed ID: 20155435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis.
    Sharifi M; Bay C; Nowroozi S; Bentz S; Valeros G; Memari S
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1586-1590. PubMed ID: 23377239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
    Anderson BJ; Keeley SR; Johnson ND
    Anaesth Intensive Care; 1991 Feb; 19(1):22-7. PubMed ID: 1901463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group.
    Braithwaite BD; Buckenham TM; Galland RB; Heather BP; Earnshaw JJ
    Br J Surg; 1997 May; 84(5):646-50. PubMed ID: 9171752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: a single center experience.
    Bratincsák A; Moore JW; El-Said HG
    Catheter Cardiovasc Interv; 2013 Nov; 82(5):782-5. PubMed ID: 22718305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.
    Zhu Y; Carmeliet P; Fay WP
    Circulation; 1999 Jun; 99(23):3050-5. PubMed ID: 10368124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter.
    Orgeron GM; Pollard JL; Pourmalek P; Sloane PJ
    Pharmacotherapy; 2015 Oct; 35(10):e153-8. PubMed ID: 26497485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator.
    Chang R; Horne MK; Mayo DJ; Doppman JL
    J Vasc Interv Radiol; 1996; 7(6):845-51. PubMed ID: 8951751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.